Dianthus Price To Sales Ratio vs Capex To Operating Cash Flow Analysis

DNTH Stock

23.60 0.24 1.03%

Dianthus Therapeutics financial indicator trend analysis is much more than just examining Dianthus Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dianthus Therapeutics is a good investment. Please check the relationship between Dianthus Therapeutics Price To Sales Ratio and its Capex To Operating Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Price To Sales Ratio vs Capex To Operating Cash Flow

Price To Sales Ratio vs Capex To Operating Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dianthus Therapeutics Price To Sales Ratio account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Dianthus Therapeutics' Price To Sales Ratio and Capex To Operating Cash Flow is -0.32. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of Dianthus Therapeutics, assuming nothing else is changed. The correlation between historical values of Dianthus Therapeutics' Price To Sales Ratio and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Dianthus Therapeutics are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Price To Sales Ratio i.e., Dianthus Therapeutics' Price To Sales Ratio and Capex To Operating Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.32

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Dianthus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Dianthus Therapeutics sales, a figure that is much harder to manipulate than other Dianthus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Operating Cash Flow

Most indicators from Dianthus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' Sales General And Administrative To Revenue is increasing as compared to previous years. The Dianthus Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to 1.70, while Selling General Administrative is projected to decrease to under 14.9 M.

	2021	2023	2024 (projected)
Interest Expense	3.6M	4.1M	2.7M
Depreciation And Amortization	2.0M	355K	337.3K

Interest Expense Depreciation And Amortization

Dianthus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Currrent Assets Other	Other Assets	Short Term Investments	Non Current Liabilities Total	Net Tangible Assets	Inventory	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.89	0.94	0.87	0.67	-0.82	-0.85	0.73	0.8	0.78	1.0	-0.77	0.25	0.97	0.56	0.2	1.0	0.47	0.6	0.54	-0.26	0.06	-0.42	0.46	0.45	0.43
Other Current Liab	0.89		0.98	0.69	0.75	-0.68	-0.83	0.55	0.66	0.77	0.89	-0.79	0.09	0.92	0.62	0.39	0.88	0.71	0.49	0.52	-0.32	0.26	-0.38	0.36	0.26	0.37
Total Current Liabilities	0.94	0.98		0.76	0.76	-0.71	-0.88	0.69	0.7	0.81	0.94	-0.78	0.14	0.95	0.66	0.33	0.93	0.67	0.52	0.52	-0.3	0.19	-0.38	0.37	0.31	0.37
Total Stockholder Equity	0.87	0.69	0.76		0.55	-0.9	-0.76	0.74	0.89	0.68	0.86	-0.79	0.39	0.88	0.59	-0.25	0.86	0.12	0.65	0.42	-0.18	-0.38	-0.26	0.26	0.65	0.23
Property Plant And Equipment Net	0.67	0.75	0.76	0.55		-0.31	-0.89	0.62	0.28	0.87	0.65	-0.45	-0.05	0.75	0.51	0.05	0.65	0.45	0.45	-0.03	0.28	-0.06	0.19	-0.18	-0.14	-0.19
Net Debt	-0.82	-0.68	-0.71	-0.9	-0.31		0.59	-0.47	-1.0	-0.4	-0.84	0.83	-0.53	-0.8	-0.49	0.04	-0.83	-0.15	-0.64	-0.72	0.51	0.16	0.59	-0.59	-0.85	-0.56
Retained Earnings	-0.85	-0.83	-0.88	-0.76	-0.89	0.59		-0.76	-0.57	-0.84	-0.84	0.67	-0.14	-0.85	-0.64	-0.1	-0.84	-0.53	-0.45	-0.28	-0.03	0.03	0.11	-0.1	-0.18	-0.1
Accounts Payable	0.73	0.55	0.69	0.74	0.62	-0.47	-0.76		0.46	0.77	0.71	-0.42	0.15	0.7	0.6	-0.13	0.71	0.31	0.37	0.16	0.05	-0.24	-0.02	0.04	0.25	0.01
Cash	0.8	0.66	0.7	0.89	0.28	-1.0	-0.57	0.46		0.37	0.81	-0.82	0.51	0.78	0.48	-0.04	0.81	0.14	0.64	0.73	-0.52	-0.15	-0.61	0.59	0.86	0.57
Non Current Assets Total	0.78	0.77	0.81	0.68	0.87	-0.4	-0.84	0.77	0.37		0.75	-0.55	-0.16	0.81	0.55	0.01	0.75	0.46	0.38	-0.04	0.25	-0.11	0.16	-0.15	-0.08	-0.16
Cash And Short Term Investments	1.0	0.89	0.94	0.86	0.65	-0.84	-0.84	0.71	0.81	0.75		-0.79	0.27	0.97	0.56	0.2	1.0	0.48	0.59	0.56	-0.29	0.06	-0.44	0.49	0.47	0.45
Net Receivables	-0.77	-0.79	-0.78	-0.79	-0.45	0.83	0.67	-0.42	-0.82	-0.55	-0.79		-0.46	-0.79	-0.79	0.01	-0.77	-0.47	-0.26	-0.48	0.49	0.13	0.3	-0.29	-0.54	-0.27
Common Stock Shares Outstanding	0.25	0.09	0.14	0.39	-0.05	-0.53	-0.14	0.15	0.51	-0.16	0.27	-0.46		0.28	0.51	-0.35	0.27	-0.07	0.13	0.39	-0.58	-0.39	-0.21	0.37	0.67	0.24
Other Current Assets	0.97	0.92	0.95	0.88	0.75	-0.8	-0.85	0.7	0.78	0.81	0.97	-0.79	0.28		0.62	0.1	0.96	0.45	0.65	0.46	-0.24	-0.04	-0.31	0.35	0.42	0.32
Other Stockholder Equity	0.56	0.62	0.66	0.59	0.51	-0.49	-0.64	0.6	0.48	0.55	0.56	-0.79	0.51	0.62		-0.12	0.55	0.58	-0.03	0.21	-0.4	-0.23	0.04	-0.01	0.29	-0.05
Total Liab	0.2	0.39	0.33	-0.25	0.05	0.04	-0.1	-0.13	-0.04	0.01	0.2	0.01	-0.35	0.1	-0.12		0.21	0.7	-0.05	0.5	-0.37	0.99	-0.6	0.56	-0.18	0.63
Total Current Assets	1.0	0.88	0.93	0.86	0.65	-0.83	-0.84	0.71	0.81	0.75	1.0	-0.77	0.27	0.96	0.55	0.21		0.47	0.6	0.56	-0.29	0.07	-0.44	0.49	0.47	0.46
Common Stock	0.47	0.71	0.67	0.12	0.45	-0.15	-0.53	0.31	0.14	0.46	0.48	-0.47	-0.07	0.45	0.58	0.7	0.47		-0.18	0.36	-0.4	0.63	-0.27	0.25	-0.15	0.29
Non Currrent Assets Other	0.6	0.49	0.52	0.65	0.45	-0.64	-0.45	0.37	0.64	0.38	0.59	-0.26	0.13	0.65	-0.03	-0.05	0.6	-0.18		0.42	0.0	-0.13	-0.38	0.37	0.5	0.37
Other Assets	0.54	0.52	0.52	0.42	-0.03	-0.72	-0.28	0.16	0.73	-0.04	0.56	-0.48	0.39	0.46	0.21	0.5	0.56	0.36	0.42		-0.8	0.44	-0.96	0.92	0.76	0.95
Short Term Investments	-0.26	-0.32	-0.3	-0.18	0.28	0.51	-0.03	0.05	-0.52	0.25	-0.29	0.49	-0.58	-0.24	-0.4	-0.37	-0.29	-0.4	0.0	-0.8		-0.33	0.73	-0.75	-0.65	-0.73
Non Current Liabilities Total	0.06	0.26	0.19	-0.38	-0.06	0.16	0.03	-0.24	-0.15	-0.11	0.06	0.13	-0.39	-0.04	-0.23	0.99	0.07	0.63	-0.13	0.44	-0.33		-0.56	0.52	-0.24	0.59
Net Tangible Assets	-0.42	-0.38	-0.38	-0.26	0.19	0.59	0.11	-0.02	-0.61	0.16	-0.44	0.3	-0.21	-0.31	0.04	-0.6	-0.44	-0.27	-0.38	-0.96	0.73	-0.56		-0.95	-0.66	-0.99
Inventory	0.46	0.36	0.37	0.26	-0.18	-0.59	-0.1	0.04	0.59	-0.15	0.49	-0.29	0.37	0.35	-0.01	0.56	0.49	0.25	0.37	0.92	-0.75	0.52	-0.95		0.64	0.98
Net Invested Capital	0.45	0.26	0.31	0.65	-0.14	-0.85	-0.18	0.25	0.86	-0.08	0.47	-0.54	0.67	0.42	0.29	-0.18	0.47	-0.15	0.5	0.76	-0.65	-0.24	-0.66	0.64		0.62
Property Plant And Equipment Gross	0.43	0.37	0.37	0.23	-0.19	-0.56	-0.1	0.01	0.57	-0.16	0.45	-0.27	0.24	0.32	-0.05	0.63	0.46	0.29	0.37	0.95	-0.73	0.59	-0.99	0.98	0.62

Click cells to compare fundamentals

Dianthus Therapeutics Account Relationship Matchups

Dianthus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	161.5M	161.6M	9.5M	83.1M	179.4M	112.5M
Other Current Liab	11.3M	7.7M	4.0M	6.6M	6.1M	6.5M
Total Current Liabilities	14.1M	11.4M	5.4M	8.2M	9.6M	9.0M
Total Stockholder Equity	141.2M	143.9M	(17.2M)	(44.4M)	168.9M	177.3M
Property Plant And Equipment Net	9.9M	8.3M	33K	956K	800K	760K
Net Debt	(65.1M)	(58.2M)	(7.6M)	(14.6M)	(131.7M)	(125.2M)
Retained Earnings	(179.5M)	(254.4M)	(17.4M)	(45.9M)	(89.4M)	(93.9M)
Accounts Payable	2.8M	3.8M	1.4M	1.2M	2.6M	2.3M
Cash	65.1M	58.2M	7.6M	15.4M	132.3M	138.9M
Non Current Assets Total	11.7M	10.1M	63K	1.1M	2.0M	1.9M
Cash And Short Term Investments	145.7M	148.8M	7.6M	75.5M	173.7M	103.1M
Common Stock Shares Outstanding	2.3M	2.7M	3.4M	874.2K	5.2M	2.8M
Liabilities And Stockholders Equity	161.5M	161.6M	9.5M	83.1M	179.4M	112.5M
Other Current Assets	4.1M	2.7M	274K	905K	3.3M	2.1M
Other Stockholder Equity	320.6M	398.3M	498.3M	(116.4M)	258.2M	221.6M
Total Liab	20.3M	17.7M	26.7M	127.5M	10.5M	10.0M
Total Current Assets	149.8M	151.5M	9.4M	82.0M	177.5M	107.1M
Accumulated Other Comprehensive Income	8K	(23K)	(30K)	(161K)	47K	49.4K
Common Stock	39K	49K	59K	61K	15K	14.3K
Non Currrent Assets Other	1.8M	1.0	(1.8M)	61K	1.1M	1.1M
Short Term Investments	80.7M	90.7M	45.3M	60.1M	41.4M	53.6M
Non Current Liabilities Total	6.2M	6.3M	21.3M	119.3M	904K	858.8K

Currently Active Assets on Macroaxis

300825	Iat Automobile Technology
600666	Aurora Optoelectronics Co
000678	Xiangyang Automobile Bearing
603818	Qumei Furniture Group
002156	TongFu Microelectronics Co

When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:

How To Invest In Dianthus

Details

Is Dianthus Stock a good investment?

Details

What is Dianthus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

7.22

Revenue Per Share

0.19

Quarterly Revenue Growth

1.351

Return On Assets

(0.19)

Return On Equity

(0.26)

The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dianthus Price To Sales Ratio vs Capex To Operating Cash Flow Analysis

Price To Sales Ratio vs Capex To Operating Cash Flow

Price To Sales Ratio vs Capex To Operating Cash Flow Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Capex To Operating Cash Flow

Dianthus Therapeutics fundamental ratios Correlations

Dianthus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dianthus Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Total Current Liabilities	+ 0.98	Other Current Liab
Property Plant And Equipment Gross	+ 0.98	Inventory

Cash	- 1.0	Net Debt
Property Plant And Equipment Gross	- 0.99	Net Tangible Assets
Net Tangible Assets	- 0.96	Other Assets
Inventory	- 0.95	Net Tangible Assets
Net Debt	- 0.9	Total Stockholder Equity
Retained Earnings	- 0.89	Property Plant And Equipment Net